Literature DB >> 21668403

New delivery systems to improve the bioavailability of resveratrol.

Ana Cláudia Santos1, Francisco Veiga, António J Ribeiro.   

Abstract

INTRODUCTION: Resveratrol (RSV) has been one of the most extensively studied polyphenols in the last 10 years, owing to its numerous and potent therapeutic activities, namely its high antioxidant properties. However, RSV's bioavailability is compromised by its physicochemical properties, such as low stability, increased oxidation on heat and light exposure, low water solubility and also its high hepatic uptake. Moreover, results obtained in human pharmacokinetic studies have shown a low amount of intact RSV in the systemic circulation, which does not justify its therapeutic activities, raising doubts about RSV's potential. RSV is already available as a nutritional supplement, although its translation to the clinic is not straightforward, owing to the lack of clinical data. AREAS COVERED: In this review, formulations that are being used for delivery of RSV are discussed. New delivery systems are presented as valid alternatives to circumvent the limitations of the physicochemical characteristics and pharmacokinetics of RSV. In this way, they are compared with classical formulations with regard to improving RSV protection and bioavailability. EXPERT OPINION: Despite promising results in preclinical settings, the applicability of RSV to humans has met with only limited success, largely owing to its inefficient systemic delivery and consequently its low bioavailability. To achieve an optimal response of RSV, new strategies are still required to enhance its bioavailability and reduce its perceived toxicity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21668403     DOI: 10.1517/17425247.2011.581655

Source DB:  PubMed          Journal:  Expert Opin Drug Deliv        ISSN: 1742-5247            Impact factor:   6.648


  29 in total

Review 1.  Implications of peptide assemblies in amyloid diseases.

Authors:  Pu Chun Ke; Marc-Antonie Sani; Feng Ding; Aleksandr Kakinen; Ibrahim Javed; Frances Separovic; Thomas P Davis; Raffaele Mezzenga
Journal:  Chem Soc Rev       Date:  2017-10-30       Impact factor: 54.564

2.  Potential therapeutic target for malignant paragangliomas: ATP synthase on the surface of paraganglioma cells.

Authors:  Stephanie Mj Fliedner; Chunzhang Yang; Eli Thompson; Mones Abu-Asab; Chang-Mei Hsu; Gary Lampert; Lee Eiden; Arthur S Tischler; Robert Wesley; Zhengping Zhuang; Hendrik Lehnert; Karel Pacak
Journal:  Am J Cancer Res       Date:  2015-03-15       Impact factor: 6.166

Review 3.  Role of dietary polyphenols in the management of peptic ulcer.

Authors:  Mohammad Hosein Farzaei; Mohammad Abdollahi; Roja Rahimi
Journal:  World J Gastroenterol       Date:  2015-06-07       Impact factor: 5.742

4.  Improvement of Resveratrol Effects When Combined with Rice Oil in Rat Models of Inflammation.

Authors:  Rodrigo B M Silva; Izaque S Maciel; Alice Ribeiro; Gabriel Rübensam; Andressa Bernardi; Fernanda B Morrone; Andre A Souto; Maria M Campos
Journal:  Inflammation       Date:  2020-02       Impact factor: 4.092

Review 5.  Targeting Cancer Via Resveratrol-Loaded Nanoparticles Administration: Focusing on In Vivo Evidence.

Authors:  Ana Cláudia Santos; Irina Pereira; Mariana Magalhães; Miguel Pereira-Silva; Mariana Caldas; Laura Ferreira; Ana Figueiras; António J Ribeiro; Francisco Veiga
Journal:  AAPS J       Date:  2019-04-23       Impact factor: 4.009

6.  Cross-linked poly(acrylic acids) microgels and agarose as semi-interpenetrating networks for resveratrol release.

Authors:  Marta Tunesi; Elisabetta Prina; Fabiola Munarin; Serena Rodilossi; Diego Albani; Paola Petrini; Carmen Giordano
Journal:  J Mater Sci Mater Med       Date:  2015-01-11       Impact factor: 3.896

Review 7.  Future directions in the prevention of prostate cancer.

Authors:  Ian M Thompson; April B Cabang; Michael J Wargovich
Journal:  Nat Rev Clin Oncol       Date:  2013-11-26       Impact factor: 66.675

Review 8.  Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence.

Authors:  Joao Tomé-Carneiro; Mar Larrosa; Antonio González-Sarrías; Francisco A Tomás-Barberán; María Teresa García-Conesa; Juan Carlos Espín
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

9.  Octreotide-functionalized and resveratrol-loaded unimolecular micelles for targeted neuroendocrine cancer therapy.

Authors:  Wenjin Xu; Jocelyn F Burke; Srikanth Pilla; Herbert Chen; Renata Jaskula-Sztul; Shaoqin Gong
Journal:  Nanoscale       Date:  2013-10-21       Impact factor: 7.790

10.  Identification of a resveratrol tetramer as a potent inhibitor of hepatitis C virus helicase.

Authors:  Sungjin Lee; Kee Dong Yoon; Myungeun Lee; Yoojin Cho; Gahee Choi; Hongje Jang; BeomSeok Kim; Da-Hee Jung; Jin-Gyo Oh; Geon-Woo Kim; Jong-Won Oh; Yong-Joo Jeong; Ho Jeong Kwon; Soo Kyung Bae; Dal-Hee Min; Marc P Windisch; Tae-Hwe Heo; Choongho Lee
Journal:  Br J Pharmacol       Date:  2015-11-25       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.